Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT00866047 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)

Study Title
A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma (NCT00866047)

Trial Description
This is a single-arm, open-label, multicenter, clinical trial to evaluate the efficacy and safety of brentuximab vedotin (also known as SGN-35) as a single agent in patients with relapsed or refractory ALCL.

This trial is sponsored by Millennium PharmaceuticalsSeattle Genetics. [1]

Study Data

  • Conditions:
    • Large-Cell Anaplastic Lymphoma
    • Non-Hodgkin’s Lymphoma (NHL)
  • Interventions:
  • Phase: II
  • Enrollment: 58
  • Start: March 2009
  • Estimated Completion: June 2016
  • Last verified: March 2015

Study Schematic

NCT00866047 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)

Click here to Return to Drug map


Last Editorial review: July 15, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015-2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar